Compare IDEXX Laboratories, Inc. (IDXX) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nucor Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Nucor Corporation trades at $271.79 (market cap $61.93B). The key difference: Nucor Corporation is the larger of the two by market cap, and Nucor Corporation pays a 0.82% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NUE | |
|---|---|---|
Market Cap | $46.22B | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $274.74 |
52-Week Low | $526.44 | $131.78 |
Enterprise Value | $47.12B | $66.34B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Nucor (NUE) trades at $272.28, down 0.85% on the day, as the steel producer shows mixed technical signals with a bullish moving average trend but overbought RSI readings. Fundamentally, the company delivered strong Q2 2026 earnings beats with EPS of $4.84 versus $4.46 expected, while revenue trends show recovery from 2024 lows. Analyst sentiment remains positive with 59% buy ratings and a $279.63 consensus target, though recent tariff developments and cyclical steel demand create headwinds.
The outlook for NUE appears cautiously optimistic with improving earnings momentum and favorable analyst coverage, though investors face risks from steel price volatility and macroeconomic pressures. The stock's current valuation at 21.7x P/E appears reasonable given the earnings recovery trajectory, but requires sustained operational execution to justify further upside beyond current resistance levels near $275.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
